We provide background reports and in-depth evaluations of our cluster's achievements and share exclusive interviews with regional industry leaders that give you interesting perspectives on topics relevant to the BioPharma Cluster and the biopharmaceutical industry.
The coordinator of Ulm Child Health
Ulm will become one of seven locations of the new German Center for Child and Adolescent Health (DZKJ). We exclusively spoke to Prof. Dr. Klaus-Michael Debatin, the Ulm site coordinator and Director of Ulm University Medical Center’s Department of Pediatrics and Adolescent Medicine.
Rentschler Biopharma and Vetter about their collaboration
The globally operating Contract Development and Manufacturing Organizations (CDMOs) Vetter and Rentschler Biopharma, two key players of the BioPharma Cluster South Germany, announced their strategic collaboration.
Frank Mathias (CEO of Rentschler Biopharm) and Peter Sölkner (Managing Director of Vetter Pharma) explain how the alliance of the two leading CDMOS will leverage Vetter's strong expertise in aseptic fill & finish and secondary packaging and Rentschler's extensive experience in drug substance manufacturing, including bioprocess development and API production.
Read the full interview now and learn more about the collaboration and its desired goal to simplify processes and optimize time-to-market.
Reports, Articles and more
Vetter-Rentschler Alliance: Competencies that build on one another
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), further enhanced their strategic alliance initiated in mid-2020.
The companies have further strengthened the established framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across functions. In parallel to starting their first joint client projects, they are also working closely on existing projects and related topics.
Read the full article and learn more about the complementary skills of bothe CDMOs along the biopharmaceutical value chain and their commitment to ccelerating the development of promising new therapies.
We have recently published the first edition of our redesigned monthly newsletter. Discover the meaning behind „BIU 2.0“ & „UCH“ and learn more about what our cluster and the biopharma/biotech industry have been up to lately.
We have recently published the October 2021 issue of our monthly newsletter. Discover how Rentschler Biopharma and Vetter have advanced their strategic collaboration. And learn more about what our cluster and the biopharma/biotech industry have been up to lately.